Kazia Therapeutics (KZIA) Return on Capital Employed (2009 - 2016)

Kazia Therapeutics' (KZIA) quarterly Return on Capital Employed came in at 92.61% in Q4 2016, down 219.02% on a QoQ basis from 29.03% in Q4 2012.

Kazia Therapeutics (KZIA) Return on Capital Employed (2009 - 2016) Analysis & Trends

Kazia Therapeutics (KZIA) has 5 years of Return on Capital Employed data on file, last reported at 92.61% in Q4 2016.

Quarterly Return on Capital Employed changed N/A year-over-year to 92.61% in Q4 2016, while the trailing twelve-month figure through Dec 2016 was 92.61% (changed N/A YoY) and the FY2025 annual result came in at 27127.84%, down 3067025.0% from the prior year.
Return on Capital Employed slipped to 92.61% in Q4 2016, from 29.03% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 29.03% in Q4 2012 to a low of 92.61% in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	10.74%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-55.45%
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	7.88%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	26.09%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-50.93%
10	Kazia Therapeutics	4.22 Bn	4.22 Bn	-	-

Download Data